TipRanks Smart Value #27: Pharma Value
1
Dear Investors,
Dear Investors,
Welcome to the 27th edition of our recently launched TipRanks Smart Value Newsletter!
1
This Week’s Top Value Pick: Teva Pharmaceuticals (TEVA)
Teva Pharmaceutical Industries (TEVA) is a leading global pharmaceutical company that develops, manufactures, and markets generic and specialty medicines, including biosimilars and innovative treatments. The company operates across therapeutic areas, including central nervous system disorders, respiratory care, and oncology, supported by one of the world’s largest portfolios of generics. With operations in more than 60 countries, Teva leverages its scale, scientific expertise, and integrated global supply chain to deliver affordable healthcare solutions and expand patient access to critical treatments. Its diversified business model, rooted in recurring demand for generics and strategic investments in specialty medicines, underpins its role as a key player in advancing global health.
1
Strategic Evolution
Teva Pharmaceutical Industries traces its roots back to 1901, when a small wholesale drug business was established in Jerusalem. That modest operation laid the groundwork for what would grow into one of the world’s largest pharmaceutical companies. The modern Teva emerged in 1976, when it merged with Assia and Zori, creating a unified platform for expansion in both generics and specialty medicines.
Through the late 20th century, Teva pursued an ambitious global growth strategy built on acquisitions. Key milestones included Human Pharmaceutical in 1996, Novopharm in 2000, and Sicor in 2004, which broadened its geographic presence and manufacturing scale at the time. A turning point came in 2006 with the $7.4 billion acquisition of IVAX, which expanded Teva’s respiratory and specialty portfolio. Just two years later, the purchase of Barr Pharmaceuticals cemented Teva’s position as a global generics leader.
In 2011, Teva deepened its specialty presence with the acquisition of Cephalon, gaining branded drugs in oncology, neurology, and pain management. Building on this specialty push, Teva entered migraine care with the acquisitions of NuPathe and Labrys Biologics in 2014. The following year, it acquired Auspex Pharmaceuticals to strengthen its central nervous system pipeline with treatments for movement disorders, and it bought Rimsa to expand in Latin America.
The most transformative chapter in Teva’s history arrived in 2016 when Teva completed two distinct buyouts from Allergan, acquiring generics business, Actavis Generics, for $40.5 billion, and its Anda distribution arm for $500 million. While the deals dramatically expanded Teva’s global footprint, they also required extensive divestitures, including sales of generic products to Sagent, Dr. Reddy’s, Impax, and Mayne Pharma, to satisfy regulators.
As debt pressures mounted in the late 2010s, Teva streamlined operations. In 2018, Teva sold its global women’s health business – including emergency contraception brands and Paragard – to Cooper Companies for $1.1 billion. The company continues to evaluate possible divestitures, underscoring management’s strategy to sharpen Teva’s focus on core generics and specialty medicines.
These acquisitions and divestitures transformed Teva into a global leader with a diversified earnings base and long-term growth potential. Today, the company is concentrating on strengthening its specialty pipeline in central nervous system disorders and respiratory care, while continuing to optimize costs and reduce debt. By leveraging its scale, scientific expertise, and broad portfolio, Teva strikes a balance between affordability and innovation, maintaining a vital role in global healthcare while positioning itself for long-term growth.
1
Growth Pivot
Teva operates a diversified business model anchored in generics and specialty medicines, supported by its active pharmaceutical ingredients arm, TAPI. The company is organized into three reporting segments: the United States, Europe, and International Markets – each managing the full portfolio of generics, biosimilars, OTC products, and innovative medicines. Regional operations are closely aligned with global R&D and marketing, enabling Teva to optimize product lifecycles while tailoring offerings to local market needs. The stability of its generics business and the expansion of its specialty portfolio underpin the company’s earnings power.
Teva’s generics portfolio spans cardiovascular, central nervous system (CNS), oncology, respiratory, and infectious diseases, with a focus on complex and high-value drugs. Generics remain the bedrock of the company, providing scale and recurring demand. While sales declined 2% YoY, the drop reflected timing of launches, exclusivity expirations, and large one-off U.S. orders, along with lower sales in Europe. Adjusted for these factors, performance was more resilient, and management expects full-year results to be flat to modestly positive. Looking ahead, biosimilars are set to play a growing role, with launches such as SELARSDI and SOLARIS and a target of $400 million in revenues by 2027, supported by 15 complex generics and eight biosimilars in the pipeline.
Alongside generics, Teva has built a growing portfolio of innovative medicines, focusing on CNS disorders, respiratory diseases, oncology, and other therapeutic areas.
Specialty medicines are central to Teva’s growth strategy because they carry higher margins than traditional generics, making their expansion a key driver of the company’s earnings. Oncology and respiratory therapies provide further depth, while new launches and geographic expansion enhance the long-term potential of this segment.
At the center of the company’s transformation is the “Pivot to Growth” strategy, first unveiled in 2023. This multi-year plan is designed to reshape Teva by 2030 through the expansion of its innovative medicines franchise, revitalization of generics and biosimilars, and operational streamlining. The goal is to build a $5 billion-plus innovative franchise by the end of the decade, creating a more balanced business that combines the stability of generics with higher-margin biopharmaceutical growth.
Operational efficiency is a key pillar for the company. Teva is pursuing $700 million in net savings between 2025 and 2027, with roughly two-thirds expected by 2026. About $70 million in savings is anticipated in the second half of 2025. The program has required upfront restructuring charges of $150 million in the second quarter, with $70–$100 million of related cash outflow expected this year. By 2027, Teva aims to achieve an operating margin of 30% through modernization and strict cost discipline, supported by a sustained annual free cash flow of at least $2.7 billion. Already, this strategy has delivered ten consecutive quarters of year-over-year revenue growth, with innovative medicines driving the momentum.
1
Growth Engines
The most recent quarter underscored the strength of Teva’s three growth engines – Huntington’s disease treatment Austedo, migraine prevention drug Ajovy, and schizophrenia medicine Uzedy. Austedo generated nearly $498 million in global sales, rising 19% year-over-year in local-currency terms, driven by adoption of its once-daily extended-release version in the United States. Ajovy delivered $155 million in sales, up 31%, and Uzedy surged 120% to $54 million. Reflecting this momentum, Teva increased its 2025 revenue outlook for these top-selling specialty drugs, indicating their stronger contribution to overall growth.
Regionally, the U.S. remains Teva’s largest market, accounting for more than half of total company sales. In the second quarter, U.S. revenues rose 2% year-over-year to $2.15 billion, supported by strong growth from Austedo, Uzedy, and Ajovy. Segment profit increased 12% to $706 million, underpinned by gross profit of $1.25 billion. Beyond its innovative franchise, Teva maintains a large U.S. generics portfolio of about 500 products across oral solids, injectables, inhaled therapies, liquids, patches, ointments, and creams, distributed through retail chains, wholesalers, and mail-order networks.
In Europe, Teva is among the top three generics players across several major markets, covering the EU, the UK, and other countries. Its OTC portfolio is broad, led by global brands and regional staples. Innovative sales in Europe are concentrated in CNS, respiratory, and oncology. In Q2, Europe revenues rose 7% year-over-year to $1.3 billion, supported by product right sales, Ajovy uptake, and stronger generics, while profits grew 6% to $364 million.
Teva’s International Markets segment includes operations in over 35 countries outside the U.S. and Europe. This segment covers both highly regulated markets, such as Canada and Israel – where generic medicines are dominant – and regions focused on branded generics, like Russia and parts of Latin America. In Q2, this segment’s revenues declined by 17% YoY, mainly due to the divestment of a business venture in Japan, while segment profit inched up by 1% year-over-year to $74 million.
Policy changes add some complexity to the outlook. Austedo was selected as one of the first 15 drugs subject to Medicare Part D price negotiations under the Inflation Reduction Act. The Centers for Medicare & Medicaid Services (CMS) will negotiate a “maximum fair price” with Teva, with talks running through 2025 and final terms due by November 1. New pricing is scheduled to take effect January 1, 2027, and will remain until generic competition or other changes occur. While this introduces uncertainty for Austedo’s Medicare revenue, the impact will not be felt until 2027 and may be tempered by existing rebates that already lower net pricing.
On tariffs, Teva emphasized its diversified supply chain, with more than half of U.S. products manufactured domestically and little reliance on China since selling its API business there four years ago. Confirmed tariffs have already been factored into 2025 guidance, and management does not anticipate a material long-term P&L impact thanks to mitigation measures.
Looking ahead, pipeline developments added further visibility to growth beyond 2025. Near-term catalysts include an FDA submission for DARI, a dual-action rescue inhaler, during Q4 2025, with potential approval and launch in 2026. Phase 3 trials for duvakitug, developed with Sanofi, are scheduled to begin late in 2025, with Phase 2b inflammatory bowel disease data due in the first half of 2026. The long-acting olanzapine injection, already showing no post-injection safety concerns, is also on track for FDA submission by year-end and potential 2026 approval. Combined, these assets could contribute more than $10 billion in peak sales, according to management estimates.
1
Financial Turnaround
Teva Pharmaceutical’s financial performance over the past three years reflects its recovery and ongoing transformation. The company’s revenues have increased at a CAGR of 2.5% over the past three years, while its EPS declined by 47.1%. This divergence between rising revenues and falling earnings stemmed mainly from higher sales costs, lower gross margins, increased promotional spending, currency headwinds, and restructuring investments that weighed on profitability.
The second quarter of 2025 highlighted progress in restoring the company’s earnings momentum. Teva reported revenue of $4.2 billion, flat YoY in U.S. dollar terms despite challenging comparisons, beating Street estimates. The company swung back to profitability, posting GAAP net income of $282 million, or $0.24 per share, compared to a loss of $0.75 in the prior-year quarter. Adjusted EPS rose 8% to $0.66, exceeding analyst estimates. Profitability benefited from a stronger mix of higher-margin innovative medicines, restructuring-related cost savings, and disciplined R&D spending. Gross margin expanded 130 basis points to 54.6%, aided by innovative product growth. Operating margin also improved to 27.1%, up from 25.3% in the same period last year.
Looking ahead, Teva reaffirmed its 2025 revenue guidance of around $17 billion and raised its EPS outlook to $2.58 from $2.55, both at the midpoint, while maintaining its free cash flow target of $1.6 billion to $1.9 billion. Gross margins are expected to remain near 54%, supported by a favorable product mix, currency tailwinds, and the Japan divestiture. Management expects continued growth in the innovative portfolio and efficiency programs to offset softness in generics. While generics are forecast to remain flat to slightly higher in 2025, a stronger performance is anticipated in the fourth quarter following weaker third-quarter comparisons. Over the longer term, Teva projects flat generics growth through 2027.
Balance sheet repair remains central to Teva’s financial strategy. As of mid-2025, gross debt declined to $17.3 billion from $17.8 billion at the end of 2024, with net debt at $15.1 billion. The company refinanced roughly $2.3 billion of maturities to better align with free cash flows. Financial leverage fell to 72% from 74% in the prior year, and net debt-to-EBITDA was just above 3x, with management targeting 2x by 2027. The progress has been recognized by credit agencies: Moody’s, S&P, and Fitch all upgraded Teva’s ratings over the past year to “Baa1,” “BB,” and “BB+,” respectively, all with stable outlooks.
This stronger balance sheet, combined with a pivot toward higher-margin innovative medicines and ongoing cost-efficiency measures, provides a solid foundation for sustaining earnings momentum and strengthening free cash flow over the coming years.
1
Value Opportunity
Teva Pharmaceutical has not paid dividends on its ordinary shares or ADRs since December 2017, reflecting management’s focus on conserving cash for debt reduction and operational investments rather than shareholder distributions. Teva also does not run an open-ended share repurchase program for common shareholders, though it continues to use equity-based incentive plans to align employee interests with long-term performance.
Teva’s cash generation has significantly strengthened over recent quarters. In the second quarter of 2025, Teva reported operating cash flow of $227 million, more than double the $103 million generated in the same period last year. Capital expenditures held steady at $97 million, while free cash flow rose 47% to $476 million, supported by stronger earnings and improved working capital management. These gains highlight the company’s increasing financial flexibility, reinforcing its ability to manage debt while investing in growth.
Teva’s stock performance over the past year reflects a positive shift in the company’s finances, driving stronger investor sentiment. Shares are modestly higher year-over-year, and while they are still significantly below the recent peak reached in December 2024, they have surged over 47% from their April lows. The rebound has been fueled by solid execution in its innovative portfolio, stabilizing generics performance, and steady progress in debt reduction.
Valuation metrics show that the stock continues to trade at a significant discount relative to the pharmaceutical sector and large-cap peers. Teva’s trailing GAAP P/E and EV/EBITDA ratios are low compared to peers like Novartis and Johnson & Johnson, while its price-to-book and price-to-cash flow ratios sit below peer averages. On a non-GAAP basis, the stock trades at nearly a 60% discount to the sector median on trailing and forward P/E ratios, at more than a 40% discount on forward PEG – which also sits well below peer averages – and EV/EBITDA and carries an 8% discount to the sector on price-to-cash flow. A discounted cash flow (DCF) analysis further supports the undervaluation thesis, suggesting the stock may be undervalued by nearly 79%.
Analysts remain broadly bullish. Consensus estimates suggest nearly 25% upside, with some projecting gains of more than 50% from current levels. This outlook is supported by Teva’s pivot toward innovative products, improving financial discipline, credit rating upgrades, a strong biosimilar pipeline, operational transformation, and sustained expectations for revenue and margin growth in the years ahead.
1
Investing Takeaway
Teva represents a classic value opportunity in the pharmaceutical sector. The company combines the stability of its global generics business with the higher-margin growth of its expanding specialty and biosimilar portfolio, creating a balanced foundation for long-term earnings. Years of restructuring and debt reduction have strengthened its balance sheet and improved financial flexibility, while its “Pivot to Growth” strategy is driving consistent momentum in innovative therapies and specialty drugs. Despite this progress, the stock continues to trade at a steep discount compared to larger peers and sector benchmarks, reflecting lingering investor caution from past challenges. With cash flow strengthening, credit ratings improving, and a pipeline of late-stage assets with multi-billion-dollar potential, Teva is well-positioned to unlock further value. For patient investors, the gap between current valuation and intrinsic fundamentals suggests meaningful upside potential.
